PDCD1 and cancer: Therefore, the combination of anti-PD-L1/PD-1 antibody and anti-VEGF antibody has been actively investigated in clinical studies of numerous types of cancer, such as non-small cell lung cancer, hepatocellular carcinoma, ovarian cancer and renal cell carcinoma (5,15,16).